Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12611000173998
Ethics application status
Approved
Date submitted
9/02/2011
Date registered
15/02/2011
Date last updated
15/02/2011
Type of registration
Prospectively registered

Titles & IDs
Public title
A Prospective Randomized Trial Comparing endoscopic LDRf and conventional Type(Japanese taxonomy) for endoscopic therapeutic esophagus variceal.
Scientific title
A Prospective Randomized Trial Comparing Survival between endoscopic LDRf and Conventional Type(Japanese taxonomy) for endoscopic therapeutic esophagus variceal after EVS therapy.
Secondary ID [1] 253572 0
none
Universal Trial Number (UTN)
Trial acronym
none
Linked study record

Health condition
Health condition(s) or problem(s) studied:
esophagus variceal 261129 0
Condition category
Condition code
Oral and Gastrointestinal 259283 259283 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
All patients in the intervention group recieve the endoscopy LDRf type to observe patients living rate after EVS therapy. Endoscopic variceal scleotherapy (EVS) was performed with 1% ethoxysclerol(4-10 ml each) 2 to 3 cm proximal to the gastroesophageal junction to eradicate the varices by intravariceal injection 20 minutes each once a week, until esophageal varicosis has disappeared.
The LDRf type is considered to be an advanced endoscopic methods for GI variceal. LDRf type characterize it: L:Location;D:Diameter;Rf :Risk factor;The therapeutic method are decided by Location and Diameter; The therapeutic occasion is decided by Risk factor.Japanese type is a conventional type. Because LDRf type can decrease the risk after esophagus variceals therapy (e.g. rebleeding,mortality,degree of varices; etc).
Intervention code [1] 258001 0
Treatment: Other
Comparator / control treatment
EVS is given for this control group by the Japanese type; eradicate the varices by intravariceal injection each once a week, until esophageal varicosis has disappeared.
Control group
Active

Outcomes
Primary outcome [1] 262093 0
Complication rate. This outcome will be assessed through monitoring by health care professionals .
Timepoint [1] 262093 0
at 1month,3moth,6month and 1 year after treatment
Primary outcome [2] 262094 0
Survival rate :1 year after treatment. This outcom will be assessed by health care professionals through telephones or by letters.
Timepoint [2] 262094 0
participants will be followed up once year after EVS ,EVS therapy by two kind of endoscopic type method(LDRf type and conventional type).
Primary outcome [3] 262095 0
esophagus variceal remote recur by gastroscopy examination.
Timepoint [3] 262095 0
at 1 year after treatment
Secondary outcome [1] 273142 0
esophagus variceal diferent rates of eradication assessed through monitoring by health care professionals .
Timepoint [1] 273142 0
at 7 days ,1month,3moth,6month and 1 year after treatment
Secondary outcome [2] 273143 0
The diferent rates of rebleeding of EV (esophagus variceal)assessed by health care professionals .
Timepoint [2] 273143 0
at 72 hours,1month,3moth,6month and 1 year after treatment
Secondary outcome [3] 273144 0
average length of stay assessed by hospital records.
Timepoint [3] 273144 0
at discharge (post-initial intervention).

Eligibility
Key inclusion criteria
esophagus variceal diagnosed by two kind of endoscopic type method (LDRf type and conventional type)simultaneity .
Minimum age
No limit
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
1.remote recurrence by gastroscopy examination.
2. after treatment of EVS for EV repeated gastroscopy examination in the same patients.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Each patient enrolled in the study will be given a serial number and will be randomized in blocks to one of the two groups: LDRf type and conventional type. Allocation is not concealed.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation by using a randomization table created by a computer software
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
15/02/2011
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
100
Accrual to date
Final
Recruitment outside Australia
Country [1] 3173 0
China
State/province [1] 3173 0

Funding & Sponsors
Funding source category [1] 258462 0
Self funded/Unfunded
Name [1] 258462 0
Enqiang Linghu
Country [1] 258462 0
China
Primary sponsor type
Individual
Name
Enqiang Linghu
Address
28 Fuxing Road,Beijing,100853,China. digestive endoscopic centre gastroenterologic and hepatologic dept. Chinese People's Liberation Army(PLA) general hospital
Country
China
Secondary sponsor category [1] 257640 0
None
Name [1] 257640 0
Address [1] 257640 0
Country [1] 257640 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 260442 0
Institute Ethics Committee,Chinese People's Liberation Army (PLA) general hospital
Ethics committee address [1] 260442 0
Ethics committee country [1] 260442 0
China
Date submitted for ethics approval [1] 260442 0
Approval date [1] 260442 0
Ethics approval number [1] 260442 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 32191 0
Address 32191 0
Country 32191 0
Phone 32191 0
Fax 32191 0
Email 32191 0
Contact person for public queries
Name 15438 0
Enqiang Linghu
Address 15438 0
28 Fuxing Road,Beijing,100853,China.
digestive endoscopic centre
gastroenterologic and hepatologic dept.
Chinese PLA general hospital
Country 15438 0
China
Phone 15438 0
+86 10 6818 2255
Fax 15438 0
+86 10 6815 4653
Email 15438 0
[email protected]
Contact person for scientific queries
Name 6366 0
Enqiang Linghu
Address 6366 0
28 Fuxing Road,Beijing,100853,China.
digestive endoscopic centre
gastroenterologic and hepatologic dept.
Chinese PLA general hospital
Country 6366 0
China
Phone 6366 0
+86 10 6818 2255
Fax 6366 0
+86 10 6815 4653
Email 6366 0
[email protected]

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.